Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,755.20
(
-1.56%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
107.96
(
1.29%
)
Bitcoin
71,094.50
(
-0.21%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 125845

Monday, 08/29/2011 4:27:17 PM

Monday, August 29, 2011 4:27:17 PM

Post# of 257257
No, but good guess. RE-LY (http://www.clinicaltrials.gov/ct2/show/NCT00262600 ) was the only phase-3 trial for Pradaxa in AF. It was blinded with respect to the two doses of Pradaxa, but open-label with respect to the warfarin arm.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now